ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $41.09 million versus the consensus estimate of $34.03 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.